Hence, these results not only highlight that RIPK2 is a novel prognostic biomarker in breast cancer, but also suggest that targeting RIPK2 may improve the outcome of advanced breast cancer patients with RIPK2 amplification or overexpression. This evidence concerns the gene RIPK2 and breast cancer.